Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Janux Therapeutics, Inc. (JANX) Insider Trading Activity
Healthcare • Biotechnology • 69 employees
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Total Value
-$76,264,838.37
Total Shares
-1,527,245
Average Trade Value
-$866,645.89
Most Active Insider
Avalon Ventures Xi, L.P.
Total Activity: $123,558,857
Largest Single Transaction
$53,700,000
by Ra Capital Management, L.P. on Oct 18, 2024
30-Day Activity
3 Transactions
Volume: 5,119 shares
Value: $805,015
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Business Officer
|
Dec 19, 2024 | 1 | $14 | 77,473 (+0.0%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 19, 2024 | 9,880 | $199,971 | 77,472 (+12.8%) | Exercise/Conversion | |
|
President and CEO
|
Dec 3, 2024 | 15,000 | $1,005,000 | 242,054 (-6.2%) | Sale | |
|
President and CEO
|
Nov 25, 2024 | 18,281 | $940,232 | 263,773 (-6.9%) | Sale | |
|
President and CEO
|
Nov 25, 2024 | 6,719 | $349,647 | 257,054 (-2.6%) | Sale | |
|
President and CEO
|
Oct 28, 2024 | 11,103 | $598,909 | 282,054 (-3.9%) | Sale | |
|
President and CEO
|
Oct 28, 2024 | 13,897 | $739,650 | 293,157 (-4.7%) | Sale | |
| Oct 18, 2024 | 104,957 | $4,696,826 | 401,321 (-26.2%) | Sale | ||
| Oct 18, 2024 | 1,200,000 | $53,700,000 | 9,317,246 (+12.9%) | Purchase | ||
| Oct 18, 2024 | 15,462 | $791,345 | 2,613,623 (-0.6%) | Sale | ||
| Oct 18, 2024 | 541,824 | $24,246,624 | 2,071,799 (-26.2%) | Sale | ||
| Oct 18, 2024 | 553,219 | $24,756,550 | 2,115,373 (-26.2%) | Sale | ||
| Oct 18, 2024 | 102,732 | $5,167,420 | 2,629,085 (-3.9%) | Sale | ||
| Oct 18, 2024 | 19,900 | $1,000,970 | 509,273 (-3.9%) | Sale | ||
| Oct 18, 2024 | 104,892 | $5,276,068 | 2,684,380 (-3.9%) | Sale | ||
| Oct 18, 2024 | 2,995 | $153,284 | 506,278 (-0.6%) | Sale | ||
| Oct 18, 2024 | 15,788 | $808,030 | 2,668,592 (-0.6%) | Sale | ||
| Oct 17, 2024 | 348 | $4,601 | 7,977 (+4.4%) | Exercise/Conversion | ||
| Oct 17, 2024 | 836 | $14,212 | 7,281 (+11.5%) | Exercise/Conversion | ||
| Oct 17, 2024 | 348 | $3,734 | 7,629 (+4.6%) | Exercise/Conversion | ||
| Oct 17, 2024 | 237 | $9,433 | 8,214 (+2.9%) | Exercise/Conversion | ||
| Oct 17, 2024 | 1,843 | $92,187 | 6,371 (-28.9%) | Sale | ||
| Oct 16, 2024 | 4,968 | $84,456 | 11,855 (+41.9%) | Exercise/Conversion | ||
| Oct 16, 2024 | 1,407 | $55,999 | 17,402 (+8.1%) | Exercise/Conversion | ||
| Oct 16, 2024 | 2,070 | $22,211 | 13,925 (+14.9%) | Exercise/Conversion | ||
| Oct 16, 2024 | 10,957 | $556,616 | 6,445 (-170.0%) | Sale | ||
| Oct 16, 2024 | 60,179 | $2,990,295 | 2,761,291 (-2.2%) | Sale | ||
| Oct 16, 2024 | 11,657 | $579,236 | 534,883 (-2.2%) | Sale | ||
| Oct 16, 2024 | 61,445 | $3,053,202 | 2,819,366 (-2.2%) | Sale | ||
| Oct 16, 2024 | 29,474 | $1,491,679 | 2,731,817 (-1.1%) | Sale | ||
| Oct 16, 2024 | 5,710 | $288,983 | 529,173 (-1.1%) | Sale | ||
| Oct 16, 2024 | 30,094 | $1,523,057 | 2,789,272 (-1.1%) | Sale | ||
| Oct 16, 2024 | 2,070 | $27,365 | 15,995 (+12.9%) | Exercise/Conversion | ||
| Sep 30, 2024 | 958 | $44,298 | 6,887 (-13.9%) | Sale | ||
| Sep 30, 2024 | 123 | $4,895 | 7,845 (+1.6%) | Exercise/Conversion | ||
| Sep 30, 2024 | 181 | $2,393 | 7,722 (+2.3%) | Exercise/Conversion | ||
| Sep 30, 2024 | 434 | $7,378 | 7,360 (+5.9%) | Exercise/Conversion | ||
| Sep 30, 2024 | 181 | $1,942 | 7,541 (+2.4%) | Exercise/Conversion | ||
| Sep 27, 2024 | 45,894 | $2,130,399 | 2,822,981 (-1.6%) | Sale | ||
| Sep 27, 2024 | 828 | $14,076 | 7,828 (+10.6%) | Exercise/Conversion | ||
| Sep 27, 2024 | 345 | $3,702 | 8,173 (+4.2%) | Exercise/Conversion | ||
| Sep 27, 2024 | 293 | $13,988 | 546,540 (-0.1%) | Sale | ||
|
Chief Scientific Officer
|
Sep 27, 2024 | 675 | $31,877 | 97,938 (-0.7%) | Sale | |
|
Chief Business Officer
|
Sep 27, 2024 | 50,000 | $210,500 | 117,592 (+42.5%) | Exercise/Conversion | |
|
Chief Business Officer
|
Sep 27, 2024 | 50,000 | $2,297,755 | 67,592 (-74.0%) | Sale | |
| Sep 27, 2024 | 345 | $4,561 | 8,518 (+4.1%) | Exercise/Conversion | ||
| Sep 27, 2024 | 234 | $9,313 | 8,752 (+2.7%) | Exercise/Conversion | ||
|
President and CEO
|
Sep 27, 2024 | 795 | $38,032 | 307,054 (-0.3%) | Sale | |
|
President and CEO
|
Sep 27, 2024 | 18,957 | $873,715 | 313,097 (-6.1%) | Sale | |
|
Chief Scientific Officer
|
Sep 27, 2024 | 4,325 | $199,840 | 98,613 (-4.4%) | Sale | |
| Sep 27, 2024 | 1,542 | $73,615 | 2,880,811 (-0.1%) | Sale | ||
| Sep 27, 2024 | 46,861 | $2,175,288 | 2,882,353 (-1.6%) | Sale | ||
| Sep 27, 2024 | 1,511 | $72,135 | 2,821,470 (-0.1%) | Sale | ||
|
President and CEO
|
Sep 27, 2024 | 5,248 | $245,895 | 307,849 (-1.7%) | Sale | |
| Sep 27, 2024 | 1,826 | $84,343 | 6,926 (-26.4%) | Sale | ||
| Sep 27, 2024 | 8,894 | $412,859 | 546,833 (-1.6%) | Sale | ||
| Sep 26, 2024 | 50,539 | $2,364,214 | 2,970,875 (-1.7%) | Sale | ||
| Sep 26, 2024 | 41,661 | $1,990,146 | 2,929,214 (-1.4%) | Sale | ||
| Sep 26, 2024 | 40,803 | $1,949,159 | 2,868,875 (-1.4%) | Sale | ||
| Sep 26, 2024 | 49,497 | $2,315,470 | 2,909,678 (-1.7%) | Sale | ||
| Sep 26, 2024 | 9,592 | $448,714 | 563,635 (-1.7%) | Sale | ||
| Sep 26, 2024 | 7,908 | $377,765 | 555,727 (-1.4%) | Sale | ||
| Sep 13, 2024 | 391 | $15,562 | 10,815 (+3.6%) | Exercise/Conversion | ||
| Sep 13, 2024 | 3,815 | $178,084 | 7,000 (-54.5%) | Sale | ||
| Sep 13, 2024 | 1,868 | $31,756 | 8,868 (+21.1%) | Exercise/Conversion | ||
| Sep 13, 2024 | 778 | $8,348 | 9,646 (+8.1%) | Exercise/Conversion | ||
| Sep 13, 2024 | 778 | $10,285 | 10,424 (+7.5%) | Exercise/Conversion | ||
| Sep 12, 2024 | 158,031 | $7,427,457 | 2,959,175 (-5.3%) | Sale | ||
| Sep 12, 2024 | 161,356 | $7,583,732 | 3,021,414 (-5.3%) | Sale | ||
| Sep 12, 2024 | 30,613 | $1,438,811 | 573,227 (-5.3%) | Sale | ||
| Sep 10, 2024 | 2,193 | $101,163 | 610,489 (-0.4%) | Sale | ||
| Sep 10, 2024 | 11,319 | $522,145 | 3,151,532 (-0.4%) | Sale | ||
| Sep 10, 2024 | 34,326 | $1,601,651 | 3,117,206 (-1.1%) | Sale | ||
| Sep 10, 2024 | 11,557 | $533,124 | 3,217,817 (-0.4%) | Sale | ||
| Sep 10, 2024 | 6,649 | $310,242 | 603,840 (-1.1%) | Sale | ||
| Sep 10, 2024 | 35,047 | $1,635,293 | 3,182,770 (-1.1%) | Sale | ||
| Sep 9, 2024 | 414 | $4,442 | 8,491 (+4.9%) | Exercise/Conversion | ||
| Sep 9, 2024 | 994 | $16,898 | 8,077 (+12.3%) | Exercise/Conversion | ||
| Sep 9, 2024 | 414 | $5,473 | 8,905 (+4.6%) | Exercise/Conversion | ||
| Sep 9, 2024 | 2,182 | $92,364 | 7,000 (-31.2%) | Sale | ||
| Sep 9, 2024 | 277 | $11,025 | 9,182 (+3.0%) | Exercise/Conversion | ||
| Sep 6, 2024 | 20,991 | $881,622 | 612,682 (-3.4%) | Sale | ||
| Sep 6, 2024 | 110,644 | $4,647,048 | 3,229,374 (-3.4%) | Sale | ||
| Sep 6, 2024 | 108,365 | $4,551,330 | 3,162,851 (-3.4%) | Sale | ||
| Jul 19, 2024 | 2,500 | $0 | 7,500 (+33.3%) | Grant | ||
| Jul 19, 2024 | 2,500 | $0 | 7,500 (+33.3%) | Grant | ||
| Jul 19, 2024 | 5,000 | $0 | 5,000 (+100.0%) | Grant | ||
| Jul 19, 2024 | 5,000 | $0 | 5,000 (+100.0%) | Grant |